BC99 Clinical Research——Weight Management

As of February 2026, more than 1,000 subjectsacross all age groups-including children, adults, andthe elderly-have been enrolled in clinical trialsinvolving BC99. Among the clinical interventionregimens, the maximum daily dosage administeredwas 48 billion CFU, with the longest interventionduration lasting up to 12 weeks.No serious adverse events (SAEs) associated withBC99 were reported in any dosage group or agesubgroup throughout the entire clinical trial period.No abnormal alterations were observed in laboratorytest parameters (covering complete blood count,hepatic and renal function tests, etc.), vital signs, orroutine physical examinations.Collectively, these robust findings verify that BC99possesses an excellent safety and tolerance inhumans.

BC99 Supports Weight Management

Following  BC99  intervention,significant  reductions  in  body  weight  were  observed   in  overweight  and  obese  subjects.Furthermore, after 4 and 8 weeks of BC99 intervention,there was a marked increase in the abundance of beneficial genera such as Bacillus,

along with a significant decrease  in  the  abundance  of harmful  bacteria.These  findings suggest that  BC99  may  achieve  its weight-reducing  effects  through  the  modulation  of  the  intestinal  microbiota